See also:

LOCAT study, 1997	TRC10781
	download pdf: gemfibrozil | cholesterol lowering intervention for cardiovascular prevention

Treatments

Studied treatment	gemfibrozil 1200 mg/d
Control treatment	placebo

Patients

Patients	post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L
Baseline characteristics	Age (mean), yrs 60  Women (%) 0%  Total cholesterol (mmol/l) 5.2 mmol/L  Diabetes(%) 0%

Method and design

Randomized effectives	197 / 198 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Follow-up duration	32 months
Geographic area	Germany
Primary endpoint	diameters

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Coronary event

7 / 197
7 / 198
classic 1,01 [0,36;2,81] 0 2 1.0

Relative risks
Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
	Studied treat.	Control treat.
Coronary event	7 / 197 (3,6%)	7 / 198 (3,5%)	1,01	[0,36;2,81]		12545
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 12545: Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic VEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.Lancet 2010 May 10;: 0:

Endpoint	studied treat.	control treat.	mean diff
total cholesterol (at 1 y)	4,83 (0,63)	5,48 (0,68)	-0,65	[-0,779;-0,52]
HDL (at 1 y)	0,98 (0,17)	0,88 (0,15)	0,10	[0,068;0,13]
LDL	3,39 (0,56)	3,83 (0,59)	-0,44	[-0,553;-0,33]

Absolute risk reduction (for a follow-up of 32 months)
Endpoint	Events rate		Absolute risk reduction (ARR)
	Studied treat.	Control treat.
Coronary event	3,55%	3,54%	0,02%

Meta-analysis of all similar trials:

cholesterol lowering intervention in cardiovascular prevention for patients with prior MI or with CHD

cholesterol lowering intervention in cardiovascular prevention for all chronical situations

HDL increasing drugs in cardiovascular prevention for all type of patients

Reference(s)

TrialResults-center ID	TRC10781
Trials register #	NA

• Frick MH, Syv�nne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kes�niemi YA, Pasternack A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.. Circulation 1997;96:2137-43
  Pubmed | Hubmed | Fulltext

(c) 2004-2016 TrialResults-center - All Rights Reserved